Attempts to align research in thrombosis and hemostasis with the In Vitro Diagnostic Medical Device Regulation (IVDR, EuropeanUnion) requirements

When new diagnostioc methods appear at the market it is important that a proper validation study is published, including performance characteristics of the biomarker measured in accordance with the new InVitro Diagnostic Medical Device Regulation (IVDR) by the European Union (EU) [1]. ECAT contributed to a commentary in the Journal of Thrombosis and Haemostasis in which the importance of the publication of such validation studies has been emphasized.

J Thromb Haemost, 2025; 23: 2107-2111.

This is publication can be approached via the following link: https://www.jthjournal.org/article/S1538-7836(25)00217-X/fulltext

[1] European Union. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746

Clotpedia Support Form

Success